Bruker Announces Acquisition of Preclinical and Molecular Imaging Research Software Provider PMOD Technologies LLC

UERICH, Switzerland, July 8th, 2019 -- Bruker today announced that it has acquired PMOD Technologies LLC, a highly respected provider of research-use-only software for preclinical and molecular imaging, with a focus on molecular quantification and pharmacokinetic modeling. The PMOD software is widely used for the analysis of positron emission tomography (PET) studies in neurology, cardiology and oncology, both for preclinical and human molecular imaging research. Founded in 2003 as a University Hospital Zuerich spin-off, PMOD Technologies is based in Zuerich and has an innovative development team in Warsaw, Poland. The acquisition confirms Bruker's commitment to provide intuitive end-to-end solutions that make image analysis and quantitative knowledge extraction in nuclear molecular imaging research more productive and precise.

Financial terms of the acquisition were not disclosed, and PMOD continues to be managed by its senior management team. The PMOD software continues to remain vendor-neutral and platform-independent, and PMOD's outstanding customer support will be maintained.

PMOD extends Bruker's portfolio of imaging software for clinical research and further enhances Bruker's expertise in nuclear molecular imaging. The portfolio now encompasses two leading-edge imaging research software packages used in magnetic resonance imaging (MRI) and nuclear molecular imaging (NMI) translational research:ParaVision® 360andPMOD.

Dr. Wulf I. Jung, President of Bruker's Preclinical Imaging Division, stated: "With the PMOD acquisition, Bruker is broadening its support for translational research with outstanding imaging tools, from highest-performance preclinical MRI, PET/SPECT and microCT systems to state-of-the-art software. Preclinical PET/MR is a fast-growing market, and the expertise of the PMOD team will further strengthen our quantitative molecular imaging solutions."

Cyrill Burger博士, CEO of PMOD, commented: "Our team is delighted to join Bruker, a leading provider of preclinical imaging solutions renowned for their innovation and dedication to excellence. Our combined expertise will accelerate the development and integration of novel molecular imaging applications, answering the growing demand for innovative research tools by translational scientists."

关于PMOD

PMOD Technologies旨在为研究人员提供一流的软件工具，用于人类和动物的生物医学成像研究。软件工具的PMOD套件是用于定量成像的综合平台，是PET动力学建模和参数映射的领先解决方案。PMOD软件包括用于图像注册的解决方案，神经病学，肿瘤学和心脏病学的自动量量定义，放射线学特征提取，3D图像可视化和计算流体动力学（CFD）建模。PMOD的客户群不断扩大，拥有600多个网站，全球估计有2,000名活跃用户。与领先的成像研究机构的互动和响应式合作确保PMOD软件的方法和范围保持领先地位。有关更多信息，请访问：www.pmod.com

About Bruker Corporation

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.